Oncotelic's Joint Venture Identifies Biomarker Predicting Tumor Sensitivity to IV Everolimus Formulation
TL;DR
Oncotelic Therapeutics' biomarker discovery offers a strategic edge by enabling targeted Sapu003 treatment for mTORC2-dominant tumors, potentially improving clinical outcomes and market positioning.
Sapu Nano's biomarker framework analyzes over 9,000 tumor samples to identify High-RICTOR/Low-RPTOR signatures, predicting sensitivity to intravenous Sapu003 for mTORC2-dominant cancers across 20 types.
This advancement could enhance cancer treatment precision, offering hope for patients with resistant tumors and potentially improving survival rates and quality of life.
Oncotelic's intravenous Sapu003 formulation overcomes oral everolimus limitations with higher tissue penetration and reduced GI accumulation, targeting multiple cancers including breast and lung.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics Inc. (OTCQB: OTLC) announced that its 45% owned joint venture, Sapu Nano, has identified a biomarker signature that predicts tumor sensitivity to Sapu003, the company's intravenous Deciparticle formulation of everolimus. The High-RICTOR/Low-RPTOR molecular signature represents the first prospective selection strategy for IV everolimus and will be presented at the 2025 San Antonio Breast Cancer Symposium.
The biomarker framework was developed through analysis of more than 9,000 tumor samples across 20 cancer types. Research indicates that mTORC2-dominant tumors, including HR+/HER2- breast cancer, lung adenocarcinoma, gastric, renal, ovarian, acute myeloid leukemia (AML), and T-cell malignancies, exhibit heightened mTOR dependency and predicted sensitivity to Sapu003. This discovery is significant because it could enable clinicians to identify patients most likely to benefit from the treatment before administration, potentially improving outcomes and reducing unnecessary treatment side effects.
Sapu003 overcomes limitations of oral everolimus through higher tissue penetration, reduced gastrointestinal accumulation, and preserved metabolic specificity. The intravenous formulation's enhanced delivery characteristics, combined with the newly identified biomarker signature, could transform how mTOR inhibitors are used in cancer therapy. For patients with the identified molecular signature across multiple cancer types, this development represents a potential pathway to more effective, targeted treatment.
The identification of this biomarker signature has implications for both clinical practice and drug development. By enabling patient stratification, it could lead to more efficient clinical trials and potentially faster regulatory approvals for targeted therapies. The research also contributes to the growing field of precision oncology, where treatments are matched to specific tumor characteristics rather than administered broadly based on cancer type alone.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. Additional information about the company is available at https://ibn.fm/OTLC. The full press release detailing this biomarker discovery can be accessed at https://ibn.fm/bIpA4.
Curated from InvestorBrandNetwork (IBN)
